News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Subscribe To Our Newsletter & Stay Updated
